- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02643667
Ibrutinib as Neoadjuvant Therapy in Localized Prostate Cancer
December 31, 2024 updated by: Washington University School of Medicine
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
30-40% of patients who undergo radical prostatetecomy (RP) with curative intent for their localized prostate cancer experience relapse of their disease.
Thus, improved therapeutic approaches are needed in this patient population.
Enhancing the patient's anti-tumor immune response prior to surgery may improve long-term outcomes following RP
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Francisco, California, United States, 94158
- University of California, San Francisco
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 18 years of age or older
- ECOG performance status 0 or 1
- Histologically documented adenocarcinoma of the prostate
- Patients must be suitable for and willing to undergo a radical prostatectomy at the completion of study therapy.
Adequate bone marrow function, defined as:
- WBC >2,500 cells/mm3
- ANC >1,500 cells/mm3
- Hemoglobin >9 mg/dL
- Platelet count >100,000 cells/mm3
- Adequate renal function, defined as serum creatinine <2 mg/dL or CrCl >30 mL/min
Adequate liver function, defined as:
- AST and ALT <2.5x institutional ULN
- Serum bilirubin <1.5x institutional ULN
- Adequate coagulation function, defined as normal PT/INR and PTT
- Ability to understand and willingness to sign a written informed consent document
- Available evaluable archival tumor tissue for correlative studies including assessment of immune infiltration and Btk expression is required. If archival tissue is unavailable, patients must be willing to undergo repeat prostate biopsy. Tissue is considered sufficient for correlative endpoint analyses if they are obtained from at least 2 prostate cores and consist of at least 15 unstained slides from the largest tumor volume and/or highest Gleason score. The availability of archival tissue or consent for repeat prostate biopsy is required for study eligibility; determination of tissue sufficiency is not required for study eligibility.
- The effects of ibrutinib on the developing human fetus is unknown. Men treated or enrolled on this protocol must agree to use adequate contraception prior to the study, for the duration of the study participation, and for 3 months after completion of treatment.
Exclusion Criteria:
- Patients with neuroendocrine or small cell features are not eligible.
- Any evidence of metastatic disease. Pre-operative staging will be undertaken per urologic standard of care.
Any prior use of hormonal therapy, including:
- GNRH agonists or GNRH antagonists (e.g., leuprorelin, degarelix)
- Antiandrogens (e.g., bicalutamide, flutamide, nilutamide)
- Novel androgen-directed therapies (e.g., abiraterone, enzalutamide)
- Any estrogen containing compounds
- 5-alpha reductase inhibitors (e.g., finasteride, dutasteride)
- PC-SPES or PC-x products. Other herbal therapies or supplements will be considered by the Principle Investigator on a case by case basis based on their potential for hormonal or anti-cancer therapies.
- Chemotherapy ≤ 21 days prior to first administration of study treatment and/or monoclonal antibody ≤ 6 weeks prior to first administration of study treatment
- Prior radiation therapy for prostate cancer
- Prior exposure to BTK inhibitors
- Prior investigational therapy for prostate cancer
- Patients may not receive any other concurrent investigational agents while on study.
- Use of systemic steroid therapy within 28 days of study screening. Patients on inhaled or topical steroids are eligible.
- Concurrent systemic immunosuppressive therapy within 21 days of the first dose of study drug.
- Major surgery requiring the use of general anesthetic within 4 weeks of study enrollment
HIV, active hepatitis B (HBV) or active hepatitis C (HCV)
- Patients with past HBV infection or resolved HBV infection, defined as the presence of hepatitis B core antibody (HBc Ab) and absence of hepatitis B surface antigen (HBsAg) are eligible. HBV DNA must be obtained in these patients prior to day 1 of ibrutinib therapy, but detection of HBV DNA in these patients will not exclude study participation.
- Patients positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
- Inability to swallow capsules or presence of malabsorption syndromes, disease significantly affecting gastrointestinal function, history of resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete small obstruction.
- Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Function Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to screening.
- Uncontrolled concurrent illness, or any underlying medical condition, which in the Principal Investigator's opinion will make the administration of ibrutinib hazardous or obscure the interpretation of adverse events.
- Recent infection requiring systemic treatment that was completed within 14 days prior to the first dose of study drug
- Concurrent active malignancy other than non-melanoma skin cancers. Patients are considered to be free of active malignancy if they have completed curative therapy and have a <30% risk of relapse.
- History of congenital bleeding diathesis.
- Known bleeding disorders (e.g. von Willebrand's disease or hemophilia).
- Concomitant use of anticoagulants including warfarin, other Vitamin K antagonists, and enoxaparin.
- Subjects who received a strong or moderate cytochrome P450 (CYP) 3A4 inhibitor within 7 days prior to the first dose of ibrutinib or patients who require treatment with a strong or moderate cytochrome P450 (CYP) 3A inhibitor.
- Vaccination with live, attenuated vaccines within 4 weeks of first dose of study drug.
- Patients on anti-platelet agents including clopidogrel and glycoprotein IIb/IIIa inhibitors. Aspirin is allowed, but should be held before surgery according to standard practices.
- Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child-Pugh classification
- Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
- Unresolved toxicities from prior anti-cancer therapy, defined as having not resolved to CTCAE v 4.03 grade 0 or 1 or to the levels dictated in the eligibility criteria with the exception of alopecia.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Phase I: Ibrutinib
|
-Ibrutinib will be supplied by Pharmacyclics Inc.
-Standard of care
|
|
Experimental: Safety Run-In and Phase II: Ibrutinib
|
-Ibrutinib will be supplied by Pharmacyclics Inc.
-Standard of care
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Dose Limiting Toxicities (Phase I and Safety Run-In)
Time Frame: Completion of DLT follow-up (2 weeks for Phase I portion and 28 days for Safety Run-In)
|
|
Completion of DLT follow-up (2 weeks for Phase I portion and 28 days for Safety Run-In)
|
|
Percentage of Participants With Positive Responses - CD20+ B Cells, IL-10+ B Cells, CD3+ T Cells, CD8+ Cytotoxic T Cells, Effector CD4+FOXP3- T Cells, and CD4+FOX3+ T Regulatory Cells
Time Frame: Pre-treatment and at time of RP (approximately 10 weeks after start of treatment)
|
In pre-treatment biopsy, RP tissue, and reference RP tissue quantitated by immunohistochemistry (IHC).
Patients will be considered to have a positive response if there is >2 fold decrease from pre-treatment to post-treatment, or considered to have a negative response if there is <2 fold decrease.
The percentage of participants who have "positive" responses are represented in the outcome measure data.
|
Pre-treatment and at time of RP (approximately 10 weeks after start of treatment)
|
|
Mean B Cell Fold Change of CD20+ B Cells
Time Frame: At RP (approximately 10 weeks after start of treatment)
|
Participants will be considered to have a positive response if there is >2 fold decrease (0.5 or less B cell fold change) or considered to have a negative response if there is <2 fold decrease.
Descriptive statistics will be used to describe pre-treatment biopsy immune infiltration, post-treatment RP immune infiltration, and immune infiltration of reference RP tissue.
|
At RP (approximately 10 weeks after start of treatment)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage of Participants With Positive Responses - CD19+ B Cells, CD25^highCD27^highCD86^High B Regulatory Cells, and CD3+, CD8+, CD4+FOXP3- and CD4+FOXP3+ T Cells Induced by Neoadjuvant Ibrutinib in Patients by Flow Cytometry
Time Frame: Pre-treatment to RP (approximately 10 weeks after start of treatment)
|
Patients will be considered to have a positive response if there is >2 fold decrease from pre-treatment to post-treatment, or considered to have a negative response if there is <2 fold decrease.
The percentage of partcipants who have "positive" responses are represented in the outcome measure data.
|
Pre-treatment to RP (approximately 10 weeks after start of treatment)
|
|
Number of Participants Who Had a 50% or Greater Decline in PSA
Time Frame: At baseline and approximately day 29
|
At baseline and approximately day 29
|
|
|
Number of Participants With a Treatment Response (Safety Lead-In and Phase II Only)
Time Frame: Completion of follow-up (approximately 10 weeks after start of treatment)
|
Pathologic down-staging and/or pathologic T0
|
Completion of follow-up (approximately 10 weeks after start of treatment)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Russell K Pachynski, M.D., Washington University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
April 12, 2023
Study Completion (Actual)
April 12, 2023
Study Registration Dates
First Submitted
December 28, 2015
First Submitted That Met QC Criteria
December 30, 2015
First Posted (Estimated)
December 31, 2015
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
December 31, 2024
Last Verified
December 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Urogenital Diseases
- Genital Diseases
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms
- Genital Diseases, Male
- Prostatic Diseases
- Male Urogenital Diseases
- Prostatic Neoplasms
- Tyrosine Kinase Inhibitors
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Ibrutinib
Other Study ID Numbers
- 201808057
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.